| | | MMG reported 2025A net profit of US$509mn, up 215% yoy, or EPS of US$0.042/shr, up 174% yoy. Excluding one-off items including net gain on foreign exchange and impairment expenses, recurring net profit would be US$816mn, mostly inline with our estimates and above Bloomberg consensus. The company declared no final dividend, same as last year. We revise up earnings forecast by 3-20% for 2026E-27E by incorporating the latest copper price forecast from the global commodity team. We also introduce our 2028 ...

Suzhou Ribo Life Science is a leading player in siRNA with key strengths including: 1) leading and differentiated pipeline candidates, 2) leading drug delivery technology platforms including both hepatic and extra-hepatic delivery, and 3) global ambitions supported by collaboration with international pharma partners. We think the key candidate, FXI-targeting siRNA RBD4059, could be a breakthrough drug for treatment of thrombotic diseases with sales potential >$6bn, a potential we think is underestimated by ...

哔哩哔哩 20260305 作者持续创作 5 至 10 年，持续积累粉丝并创造持久价值。变现方面持续拓展 创作者收入渠道，2025 年约有 300 万创作者获得收入，创作者平均收入同比 增长 21%；粉丝量达 1 万、10 万、100 万的创作者数量均实现增长，同比增 幅均超 20%。 能否介绍一下社区业务的最新进展？2025 年用户规模与用户使用时长均实现 增长，背后的关键举措是什么，未来用户增长与使用时长提升的潜力如何判断？ 2025 年社区侧实现了"用户规模回升+用户粘性创新高"的组合式增长，核心 抓手是围绕高质量 PUGV 内容供给与真实互动社区氛围的持续投入，并叠加 AI 能力对分发效率与内容发现的强化。用户规模方面，2025 年末日活跃用户同 比增速逐季提升，一季度 4%、二季度 7%、三季度 9%、四季度 10%，第四 季度 DAU 突破 1.13 亿；第四季度 MAU 同比增长 8%至 3.66 亿。用户粘性方 面，第四季度日均使用时长同比增长 8%至 107 分钟，时长超过 5 分钟的视频 观看量同比增长超 20%，反映用户内容消费向"深度与优质"升级。内容结构 上，第四季度生活类内容观看时 ...

Summary of Antengene's Conference Call Company Overview - **Company**: Antengene - **Industry**: Biotechnology, specifically focusing on T-cell engagers and immunology - **Key Product**: ATG-201, a CD19/CD3 bispecific T-cell engager for autoimmune diseases Key Points from the Conference Call Licensing Agreement with UCB - Antengene has entered a global licensing agreement with UCB for ATG-201, marking a significant milestone as the first program from the AnTenGager platform to secure a global partnership [1] - UCB will receive worldwide exclusive rights to ATG-201, while Antengene will receive $80 million in upfront and near-term milestone payments, with potential future payments of approximately $1.1 billion, excluding royalties [6][7] - The total potential deal value is approximately $1.2 billion [6] Strategic Rationale - The partnership aims to leverage Antengene's discovery and early clinical execution capabilities alongside UCB's expertise in immunology and global commercialization [6] - UCB's established immunology franchise and strong clinical execution track record (86% phase 3 success rate) provide a solid foundation for advancing ATG-201 [8] AnTenGager Platform - The AnTenGager platform is designed to create differentiated T-cell engagers, addressing limitations of first-generation T-cell engagers, such as suboptimal targeting and safety concerns [9][10] - The platform incorporates a proprietary CD3 sequence and a steric hindrance masking design, enhancing targeting efficacy and safety [10][12] - Antengene has a robust pipeline of T-cell engager programs targeting various diseases, including autoimmune diseases and solid tumors [16][18] Clinical Development and Pipeline - Antengene has conducted clinical trials across five regions, securing 32 IND approvals and advancing six first-in-human programs globally [4] - The company plans to submit clinical trial applications for ATG-201 in China and Australia in Q1 2026, with the first-in-human studies to be conducted by Antengene [6][31] - Other programs in the pipeline include ATG-106 for ovarian and kidney cancers, ATG-112 for gynecological cancers, and ATG-110 for colorectal cancer, with IND submissions planned for 2027 [16][17][18] Financial Position and Future Outlook - Antengene is well-funded, with increasing revenue from approved products in Asia-Pacific markets and additional revenue from partnerships [42] - The company aims to maximize the global impact of its innovative medicines while maintaining a focus on strategic partnerships [34][70] - Antengene is entering a new phase of growth, supported by a pivotal stage pipeline and continued scientific innovation [24][25] Additional Insights - The company remains open to both single asset and multiple asset partnership deals, emphasizing flexibility in collaboration models [33][34] - The focus for the phase 1 trial of ATG-201 will be on autoimmune diseases, with considerations for other high unmet medical needs [47][52] - Antengene's proprietary CD3 sequence is designed to minimize excessive cytokine release and T-cell exhaustion, enhancing safety and efficacy [64][65] Conclusion Antengene's strategic partnership with UCB for ATG-201 represents a significant advancement in its pipeline, leveraging both companies' strengths to enhance the development of innovative therapies for autoimmune diseases. The AnTenGager platform's unique design and the company's robust pipeline position Antengene for continued growth and leadership in the biotechnology sector.

Trip.com Group Ltd (TCOM.O) Conference Call Summary Company Overview - **Company**: Trip.com Group Ltd (TCOM.O) - **Industry**: Online Travel Agency (OTA) - **Market**: Asia Pacific - **Current Price Target**: US$75.00, revised from US$87.00 [1] Key Points Financial Performance - **Solid Earnings**: TCOM reported strong earnings with a healthy outlook for 2026, driven by robust travel demand [2] - **Revenue Growth**: Management expects revenue growth of 12-17% in Q1 2026, with a high likelihood of reaching the upper end of this guidance [2] - **Booking Growth**: QTD bookings are up 60%, with domestic hotel bookings in China growing at double-digit rates [2] - **Segment Performance**: - Hotel and packaged tours are growing in the high teens YoY - Transportation growth is projected at 8-13% [2] International Expansion - **International Business Growth**: International business accounted for approximately 40% of total revenue in 2025, up from 35% in 2024, with inbound travel showing close to triple-digit growth [3] - **Market Strategy**: The mobile-first and one-stop solution strategy is yielding positive results in APAC and Middle East markets [3] Regulatory Environment - **Regulatory Investigation**: No updates on the regulatory front; TCOM is cooperating fully with regulators. The ongoing investigation has led to a higher WACC assumption of 11.2% [5] - **Impact on Earnings**: Revenue forecasts for 2026/27 have been raised by 1%, but EPS estimates have been cut by 3-4% due to increased operating expenses [5] AI and Technology - **AI Development**: Management views AI as a catalyst for OTA businesses rather than a threat, emphasizing the importance of proprietary data and service capabilities [4] - **Investment in AI**: TCOM continues to invest in vertical AI technology to enhance travel-related search results [4] Market Position and Valuation - **Market Share**: TCOM is gaining market share due to post-COVID tailwinds and a shift in consumer spending towards travel [25] - **Valuation Metrics**: The new price target of US$75 implies a P/E ratio of 18x for 2026 and 16x for 2027 [5] - **Stock Rating**: The stock is rated as "Overweight" with a significant upside potential of 40% from the current price [6] Risks and Considerations - **Market Risks**: Potential risks include rising competition in the domestic market and macroeconomic uncertainties affecting travel demand [37] - **Investment Risks**: The ongoing regulatory investigation poses a risk to the company's operational outlook and financial performance [5] Additional Insights - **Share Repurchase Program**: TCOM announced a US$5 billion share repurchase program, representing over 10% of its market cap at the time of announcement [25] - **Long-term Growth**: The company is well-positioned to benefit from multiple growth engines, including domestic and outbound travel, as well as international expansion [25] This summary encapsulates the key insights from the conference call, highlighting the company's financial performance, growth strategies, regulatory environment, and market positioning.

卫龙美味 20260303 摘要 2026 年业绩预期乐观：预计收入增长 15%-20%，辣条业务转正，魔 芋业务高增；利润增速因规模效应及成本红利有望跑赢收入。 盈利修复核心变量：2026 年魔芋原材料成本预计明显下降，叠加高毛 利蔬菜制品占比提升及新老工厂切换带来的效率增益，毛利率具备修复 空间。 产品矩阵与竞争格局：蔬菜制品已成第一大业务（25H1 毛利 46.6%）；魔芋零食 CR3 达 75%，卫龙份额超 50%稳居第一，但面临 盐津铺子等品牌冲击。 渠道下沉与终端赋能：线下覆盖网点超 58 万个，单点 SKU 由 9.6-12.5 个提升至 16-22.8 个；重点布局增速更快的下沉市场及零食量贩专卖店 渠道。 魔芋品类创新趋势：香辣味仍为主流（占比>35%），麻酱口味快速崛 起（占比>25%）；公司 2026 年将推进麻酱、牛肝菌等新品至流通渠 道。 股东回报与估值支撑：随资本开支高峰结束，自由现金流显著改善，分 红比例有望延续高位；2026 年预测 PE 不足 15 倍，具备估值修复潜力。 Q&A 卫龙美味的公司定位、组织架构与全国化布局进展如何？ 卫龙美味是国内头部辣味休闲零食企业之一，集研 ...

Asia Pacific Equity Research 27 February 2026 China Artificial Intelligence CNY-to-date: model agentization with accelerating token consumption, raise Zhipu/MiniMax PT to HK$800/1000 Shares of Knowledge Atlas (Zhipu AI) and MiniMax have risen five-fold since IPO (vs HSI +4.3%), driven by strong investor demand for pure-play GenAI exposure and a broadening narrative that 'AI will disrupt everything'. Beyond sentiment, we see the CNY model release window marking a step change in making monetization dynamics m ...

March 2, 2026 10:10 AM GMT XPeng Inc. | Asia Pacific VLA 2.0 - A bold leap forward to capture the X factor Key Takeaways XPeng officially unveiled its long-awaited VLA 2.0, with 12x faster model inference vs. the previous generation. Per XPeng, it will enable a smoother, more efficient, human-like driving experience with better handling of complex scenarios and corner cases. VLA 2.0 should soon be available on P7, G7, and X9 Ultra in 2H of March, while other models will receive the OTA update in April. Time ...

2 March 2026 | 7:35AM HKT Equity Research Laopu Gold (6181.HK): Conducts 20-30% price hike following strong peak season; Buy On Feb 28th, Laopu conducted a 20-30% price hike (mainly falls into 25-30% range), which based on our conversation with investors, appears on average slightly higher than expectation. By category, pure gold products saw higher price hike magnitude. In our view, this helps to protect the company's GPM which management targets for 40% in 2026, vs. in 2025. Laopu's price was generally be ...

石药集团 20260302 摘要 石药集团创新管线进入兑现期，重点布局肿瘤、减肥/代谢及小核酸领域， 与阿斯利康达成 185 亿美金合作，首付款 12 亿美金，强化其全球化交 易能力和里程碑兑现预期。 石药集团在小分子、ADC 及生物药方向均有深入布局，多个项目处于全 球研发前列，部分具备 first-in-class 属性，EGFR ADC、CD47/CD20 双抗等展现 Best-in-class 潜力。2026 年将迎来早期临床数据密集读出 窗口。 EGFR ADC (6,010) 在 EGFR 突变非小细胞肺癌及后线适应症上体现出 潜在 Best-in-class 特征，并具备广谱 ADC 属性，覆盖多种实体瘤。公 司正探索前线联合治疗，2026 年或有联合治疗数据读出。 CD47/CD20 双特异性融合蛋白 (601) 在血液瘤中显示出较好疗效与安 全性，并有望拓展至 B 细胞相关自身免疫性疾病领域。 PD-1/L15 融合蛋白 (108) 主要针对尿路上皮癌方向的非肌层浸润性膀 胱癌，聚焦 BCG 不响应患者人群，预计 2026 年将发布部分数据。 与阿斯利康在 GLP-1 方向的合作是平台型合作 ...